Floatz Rating
CC41/100
Confidence
Indicative
Sponsor
Albert Einstein College of Medicine
Modality
UNKNOWN
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03612466CT.gov A Dose Finding Study of CycloSam® Combined With External Beam Radiotherapy | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Osteosarcoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Mozobil (this asset) | Albert Einstein College of Medicine | P1 | CC · 41 |
| (+)-Vincristine | Milton S. Hershey Medical Center | P2 | BB |
| Ipilimumab | Children's National Research Institute | P2 | BB |
| Olaparib | Fundación de investigación HM | P2 | BB |
| Oxaliplatin | National Cancer Institute (NCI) | P2 | B |
| Irinotecan | Milton S. Hershey Medical Center | P2 | B |
| Cyclophosphamide | M.D. Anderson Cancer Center | P2 | B |
| Etoposide | Eisai Limited | P2 | B |
| Nivolumab | Instituto do Cancer do Estado de São Paulo | P2 | B |
+42 more in the Osteosarcoma cohort
Other indications for Mozobil
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Childhood Malignant Neoplasm | — | P2 | B · 57 |
| Plasma Cell Myeloma | — | P2 | CCC · 48 |
| Metastatic Carcinoma In The Bone | — | P1 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Mozobil in Osteosarcoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/mozobil-osteosarcoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →